OncoMatch/Clinical Trials/NCT06592170
Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)
Is NCT06592170 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Linperlisib combination with obinutuzumab for lymphoma.
Treatment: Linperlisib combination with obinutuzumab — This is a single arm, open label, national multicenter clinical study included patients with marginal zone lymphoma patients (MZL) , aim is to evaluate the efficacy and safety of first-line treatment with Linperlisib combined with obinutuzumab in patients with marginal zone lymphoma (MZL).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: pi3k inhibitor
Lab requirements
Blood counts
Hemoglobin (Hb) ≥ 90 g/L; Neutrophil count (ANC) ≥ 1.5 × 10^9/L; Platelets (PLT) ≥ 100 × 10^9/L
Kidney function
Serum creatinine ≤ 1.25 × ULN or Endogenous creatinine clearance rate ≥ 60 mL/min (Cockcroft Gault formula)
Liver function
TBIL < 1.5 x ULN; ALT and AST ≤ 2.5 × ULN
Cardiac function
No ≥ grade 2 myocardial ischemia or myocardial infarction, arrhythmia [including QTc ≥ 450ms (male), QTc ≥ 470ms (female)], and ≥ grade 2 congestive heart failure [NYHA classification]
Possess sufficient bone marrow and organ functions; laboratory tests must meet the following standards: ... Hemoglobin (Hb) ≥ 90 g/L; Neutrophil count (ANC) ≥ 1.5 × 10^9/L; Platelets (PLT) ≥ 100 × 10^9/L; TBIL < 1.5 x ULN; ALT and AST ≤ 2.5 × ULN; Serum creatinine ≤ 1.25 × ULN or Endogenous creatinine clearance rate ≥ 60 mL/min (Cockcroft Gault formula); INR ≤ 1.5 × ULN; APTT ≤ 1.5 × ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify